TY - JOUR AU - Taylor, Peter C. AU - Saurigny, Didier AU - Vencovsky, Jiri AU - Takeuchi, Tsutomu AU - Nakamura, Tadashi AU - Matsievskaia, Galina AU - Hunt, Barbara AU - Wagner, Thomas AU - Souberbielle, Bernard AU - for the NEXUS Study Group PY - 2019 DA - 2019/04/18 TI - Efficacy and safety of namilumab, a human monoclonal antibody against granulocyte-macrophage colony-stimulating factor (GM-CSF) ligand in patients with rheumatoid arthritis (RA) with either an inadequate response to background methotrexate therapy or an inadequate response or intolerance to an anti-TNF (tumour necrosis factor) biologic therapy: a randomized, controlled trial JO - Arthritis Research & Therapy SP - 101 VL - 21 IS - 1 AB - Namilumab (AMG203), an immunoglobulin G1 monoclonal antibody that binds with high affinity to granulocyte-macrophage colony-stimulating factor (GM-CSF), was evaluated in a phase II randomized, double-blind, placebo-controlled study to investigate the efficacy and safety in patients with rheumatoid arthritis (RA) with an inadequate response to methotrexate (MTX-IR) or anti-tumour necrosis factor therapy (TNF-IR). SN - 1478-6362 UR - https://doi.org/10.1186/s13075-019-1879-x DO - 10.1186/s13075-019-1879-x ID - Taylor2019 ER -